<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7261">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941863</url>
  </required_header>
  <id_info>
    <org_study_id>100375</org_study_id>
    <nct_id>NCT00941863</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)</brief_title>
  <official_title>Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onyx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to define the safety profile and maximum tolerated
      dose (MTD) of sorafenib tablets in combination with carboplatin and paclitaxel chemotherapy
      in patients with advanced, refractory solid tumors.

      The secondary objectives were evaluation of pharmacokinetics (PK) and tumor response of
      these patients being treated with sorafenib in combination with paclitaxel and carboplatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Sorafenib in Combination With Paclitaxel and Carboplatin</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MTD was determined by testing increasing doses up to 400 mg twice daily (bid) on dose escalation cohorts 1 to 3 with 3 patients each. MTD reflects highest dose of drug that did not cause an unacceptable side effect (= Dose Limiting Toxicity (DLT) in more than 30% of patients; e.g., hematologic toxicities like Common Toxicity Criteria (CTC) Grade 4 Neutropenia in specific conditions, platelets &lt; 25,000 cells/mL; specific non-hematologic/biochemical toxicities CTC Grade 3 or 4; additionally, any toxicity considered by the investigator severe enough was designated a DLT); CTC Version 2 were used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Hematological and Biochemical Toxicities</measure>
    <time_frame>Start of treatment until death or within 14 days last study drug intake</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants are considered at risk for toxicity if participants had a lab measurement for the toxicity &gt;= National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade 3 as defined by the NCI CTC version 2; SGOT: Serum Glutamic-Oxaloacetic Transaminase, SGPT: Serum Glutamic-Pyruvic Transaminase, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>From start of treatment until progression or death occurs assessed every 6 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor Response (= Best Overall Response) of a subject was defined as the best tumor response (confirmed Complete Response (CR), confirmed Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time 0 to 12 Hours Post-dose (AUC 0-12) Start From Day 2 of Cycle 1</measure>
    <time_frame>At day 2 in study</time_frame>
    <safety_issue>No</safety_issue>
    <description>The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. A plot of concentration vs time after dosing is created, and the area under this curve is calculated by standard methods (eg, trapezoidal rule) to provide a measure of how much drug was in the bloodstream following dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (CMAX) Start From Day 2 of Cycle 1</measure>
    <time_frame>At day 2 in study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax refers to the highest plasma concentration of drug reached after dosing. It is obtained by collecting a series of blood samples after dosing, and analyzing them for drug content by a sensitive and specific analytical method. The highest measured concentration is referred to as the Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration (TMAX) Start From Day 2 of Cycle 1</measure>
    <time_frame>At day 2 in study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax refers to the time after dosing when a drug attains its maximum concentration in the blood. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content. The time corresponding to the highest measurable concentration (Cmax) is referred to as Tmax.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>From start of treatment until 18 Sep 2008, up to 6 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
  </other_outcome>
  <other_outcome>
    <measure>Other Adverse Events</measure>
    <time_frame>From start of treatment until 18 Sep 2008, up to 6 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency Threshold for reporting Other Adverse Events: 5%. The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib 100 mg (50-mg tablet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib 200 mg (50-mg tablet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib 400 mg (50-mg tablet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib 400 mg (200-mg tablet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet). Treatment were planned until primary completion date (PCD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib 400 mg (Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion. Treatment were planned until primary completion date (PCD). 25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib until 18 Sep 2008.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 100 mg (50-mg tablet)</intervention_name>
    <description>Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)</description>
    <arm_group_label>Sorafenib 100 mg (50-mg tablet)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 200 mg (50-mg tablet)</intervention_name>
    <description>Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)</description>
    <arm_group_label>Sorafenib 200 mg (50-mg tablet)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 400 mg (50-mg tablet)</intervention_name>
    <description>Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)</description>
    <arm_group_label>Sorafenib 400 mg (50-mg tablet)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 400 mg (200-mg tablet)</intervention_name>
    <description>Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)</description>
    <arm_group_label>Sorafenib 400 mg (200-mg tablet)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 400 mg (Expansion)</intervention_name>
    <description>Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion</description>
    <arm_group_label>Sorafenib 400 mg (Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed solid tumors

          -  Evaluable disease

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1

          -  Life expectancy minimum 12 weeks

        Exclusion Criteria:

          -  Congestive heart failure

          -  Serious arrhythmias

          -  Coronary artery disease (CAD) or ischemia

          -  HIV (human immunodeficiency virus)

          -  Hepatitis B or C

          -  Serious active infection

          -  Metastatic brain or meningeal tumors
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 24, 2016</lastchanged_date>
  <firstreceived_date>June 12, 2009</firstreceived_date>
  <firstreceived_results_date>February 3, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <keyword>Carboplatin and paclitaxel chemotherapy combination</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 3 centers in the US: the University of Wisconsin, the University of Pennsylvania, and Vanderbilt University. Enrollment began 01 Jul 2002.</recruitment_details>
      <pre_assignment_details>Expansion in this context is an increase in the number of patients exposed to the recommended dose for this combination. The purpose of the increase was also to test efficacy signals in Metastatic Melanoma (MM).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib 100 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="P2">
          <title>Sorafenib 200 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="P3">
          <title>Sorafenib 400 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="P4">
          <title>Sorafenib 400 mg (200-mg Tablet)</title>
          <description>Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)</description>
        </group>
        <group group_id="P5">
          <title>Sorafenib 400 mg (Expansion)</title>
          <description>Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Until Primary Completion Date (PCD)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Maximum Tolerated Dose</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="94"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="73"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Continued After PCD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="25">25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression, recurrence, relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib 100 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="B2">
          <title>Sorafenib 200 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="B3">
          <title>Sorafenib 400 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="B4">
          <title>Sorafenib 400 mg (200-mg Tablet)</title>
          <description>Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)</description>
        </group>
        <group group_id="B5">
          <title>Sorafenib 400 mg (Expansion)</title>
          <description>Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="12"/>
                <measurement group_id="B4" value="17"/>
                <measurement group_id="B5" value="119"/>
                <measurement group_id="B6" value="158"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49.3" spread="17.9"/>
                <measurement group_id="B2" value="52.0" spread="12.0"/>
                <measurement group_id="B3" value="52.0" spread="14.4"/>
                <measurement group_id="B4" value="52.8" spread="10.5"/>
                <measurement group_id="B5" value="52.8" spread="12.6"/>
                <measurement group_id="B6" value="52.5" spread="12.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="7"/>
                <measurement group_id="B5" value="54"/>
                <measurement group_id="B6" value="67"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="10"/>
                <measurement group_id="B5" value="65"/>
                <measurement group_id="B6" value="91"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>white</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="12"/>
                <measurement group_id="B4" value="16"/>
                <measurement group_id="B5" value="113"/>
                <measurement group_id="B6" value="150"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="2"/>
                <measurement group_id="B6" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="2"/>
                <measurement group_id="B6" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="2"/>
                <measurement group_id="B6" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Site of primary lesion</title>
          <description>Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Colon</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="1"/>
                <measurement group_id="B6" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Malignant Melanoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="10"/>
                <measurement group_id="B5" value="81"/>
                <measurement group_id="B6" value="105"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non Small Cell Lung</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="11"/>
                <measurement group_id="B6" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ovarian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="3"/>
                <measurement group_id="B6" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Renal</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="21"/>
                <measurement group_id="B6" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="2"/>
                <measurement group_id="B6" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Sorafenib in Combination With Paclitaxel and Carboplatin</title>
        <description>MTD was determined by testing increasing doses up to 400 mg twice daily (bid) on dose escalation cohorts 1 to 3 with 3 patients each. MTD reflects highest dose of drug that did not cause an unacceptable side effect (= Dose Limiting Toxicity (DLT) in more than 30% of patients; e.g., hematologic toxicities like Common Toxicity Criteria (CTC) Grade 4 Neutropenia in specific conditions, platelets &lt; 25,000 cells/mL; specific non-hematologic/biochemical toxicities CTC Grade 3 or 4; additionally, any toxicity considered by the investigator severe enough was designated a DLT); CTC Version 2 were used.</description>
        <time_frame>21 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All subjects who received at least 1 dose of any study drug treatment were included in the Intent-To-Treat/safety populations. Efficacy parameters of time to death, time to progression, and response rate (confirmed partial response [PR] plus complete response [CR]) were determined for this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib, Dose Escalation 100 mg Bid, 200 mg Bid, 400 mg Bid</title>
            <description>All participants of escalation cohorts 1, 2, 3 and 4. (Sorafenib, dose escalation 100 mg bid [twice daily], 200 mg bid, 400 mg bid including 50 tablet and 200 tablet)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Tolerated Dose (MTD) of Sorafenib in Combination With Paclitaxel and Carboplatin</title>
            <description>MTD was determined by testing increasing doses up to 400 mg twice daily (bid) on dose escalation cohorts 1 to 3 with 3 patients each. MTD reflects highest dose of drug that did not cause an unacceptable side effect (= Dose Limiting Toxicity (DLT) in more than 30% of patients; e.g., hematologic toxicities like Common Toxicity Criteria (CTC) Grade 4 Neutropenia in specific conditions, platelets &lt; 25,000 cells/mL; specific non-hematologic/biochemical toxicities CTC Grade 3 or 4; additionally, any toxicity considered by the investigator severe enough was designated a DLT); CTC Version 2 were used.</description>
            <units>mg</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="400"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Hematological and Biochemical Toxicities</title>
        <description>Participants are considered at risk for toxicity if participants had a lab measurement for the toxicity &gt;= National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade 3 as defined by the NCI CTC version 2; SGOT: Serum Glutamic-Oxaloacetic Transaminase, SGPT: Serum Glutamic-Pyruvic Transaminase, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase.</description>
        <time_frame>Start of treatment until death or within 14 days last study drug intake</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The Intent-To-Treat (ITT) population included subjects who received at least one dose of sorafenib or chemotherapy and had at least one post baseline assessment. Efficacy analyses were performed on the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 100 mg (50-mg Tablet)</title>
            <description>Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib 200 mg (50-mg Tablet)</title>
            <description>Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)</description>
          </group>
          <group group_id="O3">
            <title>Sorafenib 400 mg (50-mg Tablet)</title>
            <description>Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)</description>
          </group>
          <group group_id="O4">
            <title>Sorafenib 400 mg (200-mg Tablet)</title>
            <description>Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)</description>
          </group>
          <group group_id="O5">
            <title>Sorafenib 400 mg (Expansion, Treatment Until PCD)</title>
            <description>Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion</description>
          </group>
          <group group_id="O6">
            <title>Sorafenib 400 mg (Expansion, Treatment Continued After PCD)</title>
            <description>25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib. The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="17"/>
                  <measurement group_id="O5" value="119"/>
                  <measurement group_id="O6" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants With Hematological and Biochemical Toxicities</title>
            <description>Participants are considered at risk for toxicity if participants had a lab measurement for the toxicity &gt;= National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade 3 as defined by the NCI CTC version 2; SGOT: Serum Glutamic-Oxaloacetic Transaminase, SGPT: Serum Glutamic-Pyruvic Transaminase, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Hemoglobin &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="28"/>
                  <measurement group_id="O6" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leukocytes &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="14"/>
                  <measurement group_id="O5" value="95"/>
                  <measurement group_id="O6" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphopenia &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="11"/>
                  <measurement group_id="O5" value="99"/>
                  <measurement group_id="O6" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neutrophils/ Granulocytes &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="10"/>
                  <measurement group_id="O5" value="87"/>
                  <measurement group_id="O6" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelets &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="62"/>
                  <measurement group_id="O6" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="2"/>
                  <measurement group_id="O6" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SGOT (AST) &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="5"/>
                  <measurement group_id="O6" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SGPT (ALT) &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="5"/>
                  <measurement group_id="O6" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypophosphatemia &gt;= NCI CTC Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="8"/>
                  <measurement group_id="O5" value="52"/>
                  <measurement group_id="O6" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Response</title>
        <description>Tumor Response (= Best Overall Response) of a subject was defined as the best tumor response (confirmed Complete Response (CR), confirmed Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.</description>
        <time_frame>From start of treatment until progression or death occurs assessed every 6 weeks.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Intent-To-Treat (ITT) population included subjects who received at least one dose of sorafenib or chemotherapy and had at least one post baseline assessment. Efficacy analyses were performed on the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 100 mg (50-mg Tablet)</title>
            <description>Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib 200 mg (50-mg Tablet)</title>
            <description>Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)</description>
          </group>
          <group group_id="O3">
            <title>Sorafenib 400 mg (50-mg Tablet)</title>
            <description>Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)</description>
          </group>
          <group group_id="O4">
            <title>Sorafenib 400 mg (200-mg Tablet)</title>
            <description>Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)</description>
          </group>
          <group group_id="O5">
            <title>Sorafenib 400 mg (Expansion, Treatment Until PCD)</title>
            <description>Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion</description>
          </group>
          <group group_id="O6">
            <title>Sorafenib 400 mg (Expansion, Treatment Continued After PCD)</title>
            <description>25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib. The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="17"/>
                  <measurement group_id="O5" value="119"/>
                  <measurement group_id="O6" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tumor Response</title>
            <description>Tumor Response (= Best Overall Response) of a subject was defined as the best tumor response (confirmed Complete Response (CR), confirmed Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Complete Response (CR)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Partial Response (PR)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                  <measurement group_id="O5" value="28"/>
                  <measurement group_id="O6" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable Disease (SD)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="10"/>
                  <measurement group_id="O5" value="73"/>
                  <measurement group_id="O6" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Progressive Disease (PD)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="2"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not Assessable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                  <measurement group_id="O5" value="12"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time 0 to 12 Hours Post-dose (AUC 0-12) Start From Day 2 of Cycle 1</title>
        <description>The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. A plot of concentration vs time after dosing is created, and the area under this curve is calculated by standard methods (eg, trapezoidal rule) to provide a measure of how much drug was in the bloodstream following dosing.</description>
        <time_frame>At day 2 in study</time_frame>
        <safety_issue>No</safety_issue>
        <population>subjects with valid pharmacokinetics (PK) profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg (Excluding Expansion)</title>
            <description>Dose-escalation cohorts 3 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Curve From Time 0 to 12 Hours Post-dose (AUC 0-12) Start From Day 2 of Cycle 1</title>
            <description>The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. A plot of concentration vs time after dosing is created, and the area under this curve is calculated by standard methods (eg, trapezoidal rule) to provide a measure of how much drug was in the bloodstream following dosing.</description>
            <units>mg*h/L</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17.5" spread="2.16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (CMAX) Start From Day 2 of Cycle 1</title>
        <description>Cmax refers to the highest plasma concentration of drug reached after dosing. It is obtained by collecting a series of blood samples after dosing, and analyzing them for drug content by a sensitive and specific analytical method. The highest measured concentration is referred to as the Cmax.</description>
        <time_frame>At day 2 in study</time_frame>
        <safety_issue>No</safety_issue>
        <population>subjects with valid PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg (Excluding Expansion)</title>
            <description>Dose-escalation cohorts 3 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Concentration (CMAX) Start From Day 2 of Cycle 1</title>
            <description>Cmax refers to the highest plasma concentration of drug reached after dosing. It is obtained by collecting a series of blood samples after dosing, and analyzing them for drug content by a sensitive and specific analytical method. The highest measured concentration is referred to as the Cmax.</description>
            <units>mg/L</units>
            <param>Geometric Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.36" spread="1.79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Concentration (TMAX) Start From Day 2 of Cycle 1</title>
        <description>Tmax refers to the time after dosing when a drug attains its maximum concentration in the blood. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content. The time corresponding to the highest measurable concentration (Cmax) is referred to as Tmax.</description>
        <time_frame>At day 2 in study</time_frame>
        <safety_issue>No</safety_issue>
        <population>subjects with valid PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg (Excluding Expansion)</title>
            <description>Dose-escalation cohorts 3 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time of Maximum Concentration (TMAX) Start From Day 2 of Cycle 1</title>
            <description>Tmax refers to the time after dosing when a drug attains its maximum concentration in the blood. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content. The time corresponding to the highest measurable concentration (Cmax) is referred to as Tmax.</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24.5" lower_limit="3" upper_limit="36.08"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serious Adverse Events</title>
        <description>The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
        <time_frame>From start of treatment until 18 Sep 2008, up to 6 years</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg (Expansion, Treatment Continued After PCD)</title>
            <description>25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib. The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serious Adverse Events</title>
            <description>The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Hemoglobin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cardiovascular/Arrhythmia-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Supraventricular Arrhythmias</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cardiac-Ischemia/Infarction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Thrombosis/Embolism</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constitutional Symptoms-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dermatology/Skin-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hematuria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoptysis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemorrhage-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Febrile Neutropenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Infection Without Neutropenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Infection/Febrile Neutropenia-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperglycemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypoglycemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypokalemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Depressed Level Of Consciousness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Syncope</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chest Pain (NonCardiac/NonPleuritic)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pleural Effusion (Non-Malignant)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pneumonitis/Pulmonary Infiltrates</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Renal/Genitourinary-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Other Adverse Events</title>
        <description>Frequency Threshold for reporting Other Adverse Events: 5%. The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
        <time_frame>From start of treatment until 18 Sep 2008, up to 6 years</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib 400 mg (Expansion, Treatment Continued After PCD)</title>
            <description>25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib. The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Other Adverse Events</title>
            <description>Frequency Threshold for reporting Other Adverse Events: 5%. The responses reported in these participants were from start of treatment until 18 Sep 2008.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Allergic Reaction/Hyper-Sensitivity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Allergic Rhinitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Allergy/ Immunology-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Auditory/Hearing-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Leukocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neutrophils/Granulocytes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelets</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cardiovascular/General-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Edema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypertension</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constitutional Symptoms-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rigors, Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating (Diaphoresis)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Weight Loss</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alopecia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dermatology/Skin-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dry Skin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Flushing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hand-Foot Skin Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection Site Reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pruritus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash/Desquamation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Wound-Infectious</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Wound-Non-Infectious</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anorexia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Constipation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dehydration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspepsia/Heartburn</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dysphagia,Esophagitis,Odynophagia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stomatitis/Pharyngitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Taste Disturbance (Dysgeusia)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Epistaxis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemorrhage-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline Phosphatase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bilirubin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypoalbuminemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Infection With Unknown Anc</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Infection Without Neutropenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperglycemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypokalemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypomagnesemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyponatremia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypophosphatemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthritis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Musculoskeletal-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Confusion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Memory Loss</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mood Alteration-Anxiety, Agitation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mood Alteration-Depression</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neurology-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neuropathy-Motor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neuropathy-Sensory</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vertigo</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ocular/Visual-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vision, Blurred Vision</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Abdominal Pain Or Cramping</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia (Joint Pain)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bone Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chest Pain (NonCardiac/NonPleuritic)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia (Muscle Pain)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain-Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tumor Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cough</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnea (Shortness Of Breath)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pneumonitis/Pulmonary Infiltrates</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Voice Changes/Stridor/Larynx</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time frame for expansion group is from start of treatment until April 2008, up to 6 years.</time_frame>
      <desc>Acronyms in Adverse Event Section:
White Blood Cell (WBC) Absolute Neutrophil Count (ANC) Absolute Granulocyte Count (AGC) Alanine Transaminase (ALT) Aspartate Transaminase (AST) Grade (GR) Gastrointestinal (GI) Central Nervous System (CNS) Fibrillation/Flutter (FIB/FLUTT) Neutropenia (Neu) documented (doc)</desc>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib 100 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="E2">
          <title>Sorafenib 200 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="E3">
          <title>Sorafenib 400 mg (50-mg Tablet)</title>
          <description>Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)</description>
        </group>
        <group group_id="E4">
          <title>Sorafenib 400 mg (200-mg Tablet)</title>
          <description>Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)</description>
        </group>
        <group group_id="E5">
          <title>Sorafenib 400 mg (Expansion)</title>
          <description>Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTC v.2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="76" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hemoglobin (HGB)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Coagulation - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular arrhythmias (SVT/A FIB/FLUTT)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiovascular/arrhythmias - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiac - ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pericardial effusion/pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Phlebitis (superficial)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cardiovascular/general - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhea, patients without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painfull swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ileus (or neuroconstipation)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer (radiographic or endoscopic)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in absence of neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Fatigue (Lethargy, Malaise, Asthenia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chest pain (non-cardiac and nonpleuritic)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tumor pain (onset/exacerb. tumor pain)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia (fever w/ unknow origin)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection (doc clinic or microbio) w/ GR 3 or 4 Neu</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection/febrile neutropenia - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Seizure(s)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title vocab="Erwarte nicht">Speech impairment (dysphasia or aphasia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neuropathy - motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neuropathy - sensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/genitourinary - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ureteral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/skin - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound - infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound - non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Hemorrhage/belleding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hemorrhage - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Melena/GI bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rectal bleeding/hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding with grade 3 or 4 thrombo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hematuria (in absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTC v.2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="118" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granolocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hemoglobin (HGB)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="73" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Phlebitis (superficial)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/hearing - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Inner ear/hearing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision, blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ocular/visual - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="78" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhea, patients without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Taste disturbance (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Diarrhea, patients with colostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Ascites (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mouth dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (Lethargy, Malaise, Asthenia)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Fever (in absence of neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Rigors, chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Myalgia (muscle pain)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pain - other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Chest pain (non-cardiac and non-pleuritic)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tumor pain (onset/exacerb. tumor pain)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neuropathic pain (jaw, neuro, limb pain)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hyper-sensitivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Allergy/immunology - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Infection/febrile neutropenia - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Muscle weakness (not due to neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy - sensory</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="73" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety, agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neuropathy - motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Neurology - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Memory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Speech impairment (dysphasia or aphasia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Voice changes/stridor/larynx (hoarseness)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pulmonary - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hiccoughs (hiccups, singultus)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dermatology/skin - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Wound - infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Bruising (in absence of GR 3 or 4 thrombo)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Hemorrhage - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor recognizes right of principle investigator (PI) to publish results on completion of study, however, PI must provide draft of the communication to sponsor for approval 30 days prior to submission for publication. In case of difference of opinion between sponsor and PI, the parties will seek a solution satisfactory to both.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
